Evolus, Inc.

Good afternoon, everyone, and thank you for standing by. Welcome to Eberle's third quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, today's conference is being recorded and webcast live. I would now like to turn the conference over to Narek Segarian, Vice President, and head of Global Investor Relations and Corporate Communications. Please go ahead.

Thank you, Operator, and welcome to everyone joining us on today's call to review Evelis' third quarter 2024 financial results. Our third quarter 2024 press release is now on our website at evelis.com. With me today are David Modazzetti, President and Chief Executive Officer, Rui Avalar, Chief Medical Officer and Head of R&D, and Sandra Beaver, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to the risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results. A reconciliation of GAAP to non-GAAP measures is included in today's earnings release. As a reminder, our earnings release and SEC filings are available on the SEC's website and on our investor relations website. Following the conclusion of today's call, a replay will be available on our website at investors.evalus.com. With that, I'll turn the call over to our CEO, David Modazzetti.

Thank you, Narg. Good afternoon, everyone. Thank you for joining us on our third quarter 2024 earnings conference call. In our fifth year of commercialization, Avalos has evolved from a single product company to a multi-product portfolio with last week's approval of a scheme in Europe. This important milestone positions us as only one of five companies globally offering a portfolio of injectable aesthetic products. Our experience in Europe with esteem will inform our U.S. introduction of Evelisse. Now turning to our results. Year-to-date, we have delivered market-leading growth, increasing revenue by 33% compared to 2023. For the third quarter, we achieved $61 million in net revenue, representing 22% growth over the prior year and multiples above the growth of the market. Our consistent performance underscores the strength of our long-term strategy by successfully engaging consumers, driving repeat demand, and building lasting brand loyalty, which forms a scalable foundation for the upcoming launch of Evelisse. What truly differentiates Evelisse is our dedication to building a performance beauty company. Our unique cash pay model strengthens our partnerships with customers and enhances their experience through co-branded media and an innovative digital platform. In the third quarter, we added over 600 purchasing accounts and maintained a strong reorder rate over 70%. As we announced last week, our Eveless Rewards Program recently achieved over 1 million consumers enrolled. Looking ahead to the fourth quarter, we are meaningfully expanding our loyalty offerings with the launch of Club Evalus, the first subscription-based consumer membership program from a manufacturer. In our one-year pilot test of 250 consumers, we demonstrated that consumers doubled their treatment frequency compared to the industry average. These results highlight the program's effectiveness in enhancing patient retention increasing treatment frequency, and fostering deeper consumer loyalty. By offering transparent pricing and consistent consumer savings, we are increasing value to practices and reinforcing Givaud as part of her routine duty regimen. We're thrilled to have launched Club Avalos earlier this month, and I'm incredibly proud of the collaboration between our creative and digital innovation teams. At Evelisse, we pride ourselves on our commitment to innovation. The dermal filler market presents a significant opportunity to enter the second largest category in aesthetics. Evelisse, our next generation cold technology, is the first major innovation in hyaluronic acids in over a decade. With Evelisse warm and smooth, well into the FDA review process, we expect a U.S. launch by September 2025. Our customer-first approach and operational synergies between Jeveaux and Evelisse enables us to execute this launch efficiently while driving operating margin expansion. Now I'd like to turn the call over to Rui to share more details on the approval of Esteem.